REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study
Launched by IMMUNE RESPONSE BIOPHARMA, INC. · Nov 11, 2014
Trial Information
Current as of September 08, 2025
Unknown status
Keywords
ClinConnect Summary
This is a 26 subject Multi Center double-blind randomized, Safety \& Efficacy, pediatric HIV/AIDS Phase II study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen and secondarily to examine changes in CD4+ \& CD8+ T cell counts, determine Remune vaccines effect of multiple inoculations of HIV-1 immunogen on viral replication in children with HIV-1 infection \& immunogenicity of Remune. Multi-center, randomized , double-blind, placebo-controlled, two arm parallel design study of Remune.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children clinically diagnosed with HIV that are 3 months of age to the age 16 years old
- • Subjects on any approved FDA antiviral medication except triple cocktail HAART drugs
- Exclusion Criteria:
- • Truvada
- • Triple cocktail HAART drugs
- • Healthy subjects
About Immune Response Biopharma, Inc.
Immune Response Biopharma, Inc. is a leading biopharmaceutical company dedicated to advancing innovative therapies that harness the power of the immune system to combat various diseases. With a focus on developing cutting-edge treatments for autoimmune disorders, cancer, and infectious diseases, the company utilizes state-of-the-art technologies and a robust research framework to pioneer novel immunotherapies. Committed to improving patient outcomes, Immune Response Biopharma collaborates with academic institutions and industry partners to drive clinical research and bring transformative therapies from the lab to the clinic.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Patients applied
Trial Officials
Richard M Bartholomew, PhD
Study Director
Immune Response BioPharma, Inc. Chief R&D Officer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials